You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥(09688.HK)瑞普替尼治療非小細胞肺癌新藥上市申請獲受理
再鼎醫藥(09688.HK)(ZLAB.US)公布,旗下產品瑞普替尼(Repotrectinib)用於治療ROS1陽性的局部晚期或轉移性非小細胞肺癌的新藥上市申請,已獲得國家藥監局受理。 再鼎醫藥總裁兼全球腫瘤研發負責人Rafael Amado表示,申請獲受理進一步支持瑞普替尼可能成為治療中國ROS1陽性非小細胞肺癌患者的潛在同類最優療法,由於目前獲批療法的獲益持久性有限,發生耐藥及不可避免的腫瘤進展,部分患者存在巨大的未被滿足的需求,將在審評過程中積極配合藥監局。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account